Litmys and PharmaACE Announce Strategic Collaboration to Strengthen Commercial Forecasting and Life Sciences Decision-Making

Collaboration combines Litmys' proprietary adoption readiness analytics and market research expertise with PharmaACE's advanced forecasting and commercial analytics capabilities

SANTA FE, N.M., Nov. 11, 2026 /PRNewswire/ -- Litmys, a life sciences commercial strategy consulting firm specializing in commercial readiness and adoption analytics, and PharmaACE, a global life sciences consulting and analytics firm, today announced a strategic collaboration designed to help life sciences companies make more informed development, investment, and commercialization decisions. The collaboration brings together Litmys' expertise in understanding and quantifying the factors that drive real-world product adoption and PharmaACE's advanced forecasting, commercial modeling, and analytics capabilities. By connecting these disciplines, the companies aim to help life sciences organizations develop more realistic assessments of market potential and translate those insights into stronger commercial strategies.

"Approval does not equal adoption, and a forecast is only as good as the assumptions behind it," said Harris Kaplan, Managing Partner at Litmys. "Our work focuses on understanding what will actually drive physicians, payers, and patients to embrace a new product. Combining that perspective with PharmaACE's sophisticated forecasting and analytics capabilities allows us to connect the drivers of adoption more directly to commercial expectations and help clients make better decisions while they still have time to influence the outcome."

Traditional pharmaceutical forecasts often rely heavily on clinical profiles, market size, and assumptions about future market share. Yet commercial success ultimately depends on whether physicians prescribe, payers provide access, and patients adopt new therapies. Understanding how these stakeholders influence one another, and how those interactions affect demand, is essential to building more reliable forecasts.

Litmys' proprietary RAMPx™ (Realistic Assessment of Market Potential) methodology evaluates the drivers of real-world adoption, identifying product advantages, barriers to adoption, and stakeholder willingness to change current behaviors. PharmaACE contributes sophisticated forecasting models, commercial analytics, and strategic consulting capabilities to help translate these insights into actionable market projections and business decisions.

"The strongest forecasts do more than project market share. They reflect a clear understanding of the factors that will influence whether a product is prescribed, reimbursed, and used. Our collaboration with Litmys brings additional depth to those assumptions, combining their expertise in stakeholder adoption with our forecasting and analytics capabilities to help clients make more confident commercial decisions," said Michael Devinoff, Chief Strategy Officer at PharmaACE.

What This Means for Life Sciences Companies

• More Realistic Commercial Forecasts: Integrating stakeholder adoption insights with advanced forecasting models can help companies develop market projections grounded in how customers are likely to behave, rather than relying solely on traditional market assumptions.
• Earlier Identification of Commercial Risk: Evaluating adoption drivers and barriers alongside forecast assumptions helps identify potential challenges before pivotal development and commercialization decisions are finalized.
• Better-Informed Investment and Portfolio Decisions: Connecting commercial readiness assessments with financial and market modeling provides a more complete understanding of an asset's commercial potential and the factors that could influence its value.
• Integrated Strategic and Analytical Support: Clients can access complementary expertise in market research, adoption assessment, forecasting, and commercial analytics to support decisions from clinical development through launch and beyond.

Through the collaboration, the companies will offer complementary and jointly delivered services to pharmaceutical, biotechnology, and other life sciences clients seeking to improve the quality of their commercial assessments, forecasts, and strategic decisions. A consistent assessment framework can also help companies compare opportunities across assets and prioritize resources across global portfolios.

About Litmys

Litmys is a life sciences consulting firm specializing in drug and device development risk assessment and commercial readiness analytics. Its proprietary predictive scoring model provides early insight into a therapeutic asset's real-world commercial viability, enabling life sciences companies to reduce costly failure rates, strengthen R&D pipeline ROI, and make investment decisions with confidence. Litmys is headquartered in Santa Fe, New Mexico, with an additional office in Minneapolis, Minnesota. Learn more at www.litmys.com.

About PharmaACE

PharmaACE is a leading life sciences consulting and analytics firm that helps pharmaceutical and biotech decision-makers answer their most critical business questions. Founded in 2013 and headquartered in Princeton, New Jersey, with offices in Germany, Canada, Portugal and India - PharmaACE combines expert-led strategic consulting, advanced analytics, and agentic AI solutions to support clients across the development and commercialization lifecycle.

The firm specializes in forecasting, market access, competitive intelligence, commercial analytics, and a range of advisory services - across a broad set of therapeutic areas inclusive of Oncology, Immunology, CNS, Cardiometabolic, and Rare Diseases. PharmaACE offers a suite of proprietary platforms and AI/agentic capabilities which integrate data, analytics, and intelligence - for forecasting, performance tracking, and market planning. Learn more at www.pharmaace.com.

Media Contact
Russo Partners
Elio Ambrosio or David Schull
(760) 846-9265
[email protected] 
[email protected]

SOURCE Litmys